JP2012519484A - マイクロｒｎａ応答要素を含む弱毒化生インフルエンザウイルスワクチン - Google Patents

マイクロｒｎａ応答要素を含む弱毒化生インフルエンザウイルスワクチン Download PDF

Info

Publication number
JP2012519484A
JP2012519484A JP2011552950A JP2011552950A JP2012519484A JP 2012519484 A JP2012519484 A JP 2012519484A JP 2011552950 A JP2011552950 A JP 2011552950A JP 2011552950 A JP2011552950 A JP 2011552950A JP 2012519484 A JP2012519484 A JP 2012519484A
Authority
JP
Japan
Prior art keywords
sequence
mir
mre
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011552950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012519484A5 (enExample
Inventor
テノエヴァー，ベンジャミン
Original Assignee
マウント・シナイ・スクール・オヴ・メディシン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マウント・シナイ・スクール・オヴ・メディシン filed Critical マウント・シナイ・スクール・オヴ・メディシン
Publication of JP2012519484A publication Critical patent/JP2012519484A/ja
Publication of JP2012519484A5 publication Critical patent/JP2012519484A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16361—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2011552950A 2009-03-06 2010-03-08 マイクロｒｎａ応答要素を含む弱毒化生インフルエンザウイルスワクチン Pending JP2012519484A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15823309P 2009-03-06 2009-03-06
US61/158,233 2009-03-06
PCT/US2010/000709 WO2010101663A2 (en) 2009-03-06 2010-03-08 Live attenuated influenza virus vaccines comprising microrna response elements

Publications (2)

Publication Number Publication Date
JP2012519484A true JP2012519484A (ja) 2012-08-30
JP2012519484A5 JP2012519484A5 (enExample) 2013-04-25

Family

ID=42710158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011552950A Pending JP2012519484A (ja) 2009-03-06 2010-03-08 マイクロｒｎａ応答要素を含む弱毒化生インフルエンザウイルスワクチン

Country Status (5)

Country Link
US (1) US8883995B2 (enExample)
EP (1) EP2403527A4 (enExample)
JP (1) JP2012519484A (enExample)
CA (1) CA2754826A1 (enExample)
WO (1) WO2010101663A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016088380A1 (ja) * 2014-12-03 2016-06-09 公益財団法人ヒューマンサイエンス振興財団 ムンプスウイルスの弱毒化方法、ムンプスウイルス、及び、生ワクチン
JP2019522986A (ja) * 2016-07-08 2019-08-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 弱毒化突然変異体ジカウイルスをコードするゲノム配列
JP2024535145A (ja) * 2021-09-03 2024-09-27 バヴァリアン・ノルディック・アクティーゼルスカブ 改変ワクシニアウイルスアンカラ（ｍｖａ）による細胞傷害性導入遺伝子発現を下方調節するためのマイクロｒｎａの利用
US12168049B2 (en) 2018-03-08 2024-12-17 Codagenix Inc. Attenuated flaviviruses
US12178869B2 (en) 2017-12-22 2024-12-31 Codagenix Inc. Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004235396B2 (en) 2003-04-29 2010-11-25 Sarepta Therapeutics, Inc. Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
US8883995B2 (en) * 2009-03-06 2014-11-11 Icahn School Of Medicine At Mount Sinai Live attenuated influenza virus vaccines comprising microRNA response elements
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2011131193A1 (en) * 2010-04-24 2011-10-27 Statens Serum Institut Diagnosing and treating fibrotic diseases using micro-rna 17
PT3351636T (pt) 2010-05-14 2020-09-24 Univ Oregon Health & Science Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos
WO2012051491A1 (en) * 2010-10-14 2012-04-19 The United States Of America, As Represented By The Secretary National Institutes Of Health Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
JP6006292B2 (ja) * 2011-04-08 2016-10-12 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） インフルエンザウイルス複製を阻害するための方法および医薬組成物
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
US20130280215A1 (en) * 2011-10-18 2013-10-24 Geovax, Inc. Mva vectors expressing polypeptides and having high level production in certain cell lines
EP2859103B1 (en) 2012-06-06 2019-04-17 Boehringer Ingelheim International GmbH CELL ENGINEERING USING RNAs
US10286064B2 (en) 2012-06-15 2019-05-14 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
AU2013317805B2 (en) 2012-09-21 2018-07-26 Pds Biotechnology Corporation Improved vaccine compositions and methods of use
LT2964769T (lt) 2013-03-05 2018-12-10 Oregon Health & Science University Citomegalo viruso vektoriai, leidžiantys kontroliuoti ląstelių nukreipimą į taikinį
CA2898130A1 (en) 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Vaccines with biomolecular adjuvants
CN104694541A (zh) 2013-12-09 2015-06-10 江苏命码生物科技有限公司 禽流感病毒miRNA及其鉴定、检测和应用
WO2015195881A1 (en) * 2014-06-18 2015-12-23 The Regents Of The University Of California Methods and compositions for inhibiting infection by influenza and viruses
NZ728208A (en) 2014-07-16 2018-07-27 Univ Oregon Health & Science Human cytomegalovirus comprising exogenous antigens
WO2016061200A1 (en) * 2014-10-14 2016-04-21 Texas Tech University System Live attenuated viral vaccine created by self-attenuation with species-specific artificial microrna
EA201791806A1 (ru) 2015-02-10 2017-12-29 Орегон Хелс Энд Сайенс Юниверсити Способы и композиции, полезные при генерировании неканонических cd8+ т-клеточных ответов
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
US10927151B2 (en) 2015-06-09 2021-02-23 Sanofi Pasteur Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
US10383935B2 (en) 2015-09-23 2019-08-20 Regents Of The University Of Minnesota Methods of making and using live attenuated viruses
US10086063B2 (en) * 2015-09-23 2018-10-02 Regents Of The University Of Minnesota Methods of making and using live attenuated viruses
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
US10688164B2 (en) * 2015-11-20 2020-06-23 Oregon Health & Science University CMV vectors comprising microRNA recognition elements
WO2018075591A1 (en) 2016-10-18 2018-04-26 Oregon Health & Science University Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
TW201924722A (zh) 2017-12-05 2019-07-01 美商Ｐｄｓ生技公司 用於刺激第i型干擾素基因之方法及包含陽離子脂質的組合物
KR102831806B1 (ko) 2018-04-20 2025-07-09 텍사스 테크 유니버시티 시스템 병원체에 대한 자가-약독화된 예방 및 치료 백신
WO2020244605A1 (zh) * 2019-06-04 2020-12-10 凌斌 重组非结构蛋白1、含此的重组流感病毒及免疫组成物及其用于制备流感病毒疫苗组成物的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525175A (ja) * 2003-04-23 2007-09-06 ウィスコンシン アルムニ リサーチ ファウンデイション 突然変異した膜タンパク質をその機能性の一部ウイルス
US20080045472A1 (en) * 2006-03-31 2008-02-21 Council Of Scientific And Industrial Research Bharat Biotech Targets for human micro rnas in avian influenza virus (h5n1) genome
WO2008121992A2 (en) * 2007-03-30 2008-10-09 Research Foundation Of State University Of New York Attenuated viruses useful for vaccines
WO2008140622A2 (en) * 2006-12-22 2008-11-20 The Penn State Research Foundation Modified polymerases and attenuated viruses and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE546528T1 (de) 2002-11-13 2012-03-15 Univ Jefferson Zusammensetzungen und verfahren zur diagnose und behandlung von krebs
US8145436B2 (en) * 2003-07-15 2012-03-27 The Trustees Of The University Of Pennsylvania Method and systems for identifying micro-RNA targets and synthesizing novel micro-RNAs and uses of the same
US8106180B2 (en) 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
US7279275B2 (en) * 2003-11-03 2007-10-09 Washington University Methods and compositions for detection of segmented negative strand RNA viruses
WO2006033691A2 (en) * 2004-07-02 2006-03-30 Niman Henry L Copy choice recombination and uses thereof
US20070213293A1 (en) 2005-04-08 2007-09-13 Nastech Pharmaceutical Company Inc. Rnai therapeutic for respiratory virus infection
US20070054872A1 (en) * 2005-08-24 2007-03-08 Mirus Bio Corporation Regulatable or conditional expression systems
US9072701B2 (en) * 2006-04-21 2015-07-07 St. Jude Children's Research Hospital Avian influenza viruses, vaccines, compositions, formulations, and methods
EP2115141A4 (en) 2007-02-20 2010-08-04 Monsanto Technology Llc miRNA FROM INVERTEBRATES
US20120115131A1 (en) * 2007-05-31 2012-05-10 Yale University Genetic lesion associated with cancer
US9090894B2 (en) * 2007-12-17 2015-07-28 California Institute Of Technology Modulating immune system development and function through microRNA MIR-146
WO2009111892A1 (en) * 2008-03-14 2009-09-17 Ottawa Health Research Institute Microrna mediated oncolytic targeting
US8883995B2 (en) * 2009-03-06 2014-11-11 Icahn School Of Medicine At Mount Sinai Live attenuated influenza virus vaccines comprising microRNA response elements

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525175A (ja) * 2003-04-23 2007-09-06 ウィスコンシン アルムニ リサーチ ファウンデイション 突然変異した膜タンパク質をその機能性の一部ウイルス
US20080045472A1 (en) * 2006-03-31 2008-02-21 Council Of Scientific And Industrial Research Bharat Biotech Targets for human micro rnas in avian influenza virus (h5n1) genome
WO2008140622A2 (en) * 2006-12-22 2008-11-20 The Penn State Research Foundation Modified polymerases and attenuated viruses and methods of use thereof
WO2008121992A2 (en) * 2007-03-30 2008-10-09 Research Foundation Of State University Of New York Attenuated viruses useful for vaccines

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6014031555; Ｊｏｕｒｎａｌ　ｏｆ　Ｖｉｒｏｌｏｇｙ Ｖｏｌ．４４，　Ｎｏ．１, 1982, ｐｐ．３２１-３２９ *
JPN6014031556; Ｓｃｉｅｎｃｅ Ｖｏｌ．２７９, 1998, ｐｐ．３９３-３９６ *
JPN6014031558; ＰＮＡＳ ＶＯｌ．１０１，　Ｎｏ．２１, 2004, ｐｐ．８１５６-８１６１ *
JPN6014031560; Ｎａｔｕｒｅ　Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｖｏｌ．２７，　Ｎｏ．６, 200905, ｐｐ．５７２-５７６，　ＯＮＬＩＮＥ　ＭＥＴＨＯＤＳ *
JPN6014031562; Ｎｕｃｌｅｉｃ　Ａｃｉｄｓ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．３５, 2007, Ｄ３８１-Ｄ３８５ *
JPN6015016336; Ｎａｔｕｒｅ　Ｍｅｄｉｃｉｎｅ Ｖｏｌ．１４，　Ｎｏ．１１, 2008, ｐｐ．１２７８-１２８３ *
JPN6015016337; Ｃｅｌｌ　Ｈｏｓｔ　＆　Ｍｉｃｒｏｂｅ Ｖｏｌ．４, 2008, ｐｐ．２３９-２４８ *
JPN6015016338; Ｃｅｌｌ Ｖｏｌ．１３６，　Ｎｏ．２, 200901, ｐｐ．２１５-２３３ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016088380A1 (ja) * 2014-12-03 2016-06-09 公益財団法人ヒューマンサイエンス振興財団 ムンプスウイルスの弱毒化方法、ムンプスウイルス、及び、生ワクチン
JPWO2016088380A1 (ja) * 2014-12-03 2017-09-14 公益財団法人ヒューマンサイエンス振興財団 ムンプスウイルスの弱毒化方法、ムンプスウイルス、及び、生ワクチン
JP2019522986A (ja) * 2016-07-08 2019-08-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 弱毒化突然変異体ジカウイルスをコードするゲノム配列
JP7046848B2 (ja) 2016-07-08 2022-04-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 弱毒化突然変異体ジカウイルスをコードするゲノム配列
US12178869B2 (en) 2017-12-22 2024-12-31 Codagenix Inc. Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
US12168049B2 (en) 2018-03-08 2024-12-17 Codagenix Inc. Attenuated flaviviruses
JP2024535145A (ja) * 2021-09-03 2024-09-27 バヴァリアン・ノルディック・アクティーゼルスカブ 改変ワクシニアウイルスアンカラ（ｍｖａ）による細胞傷害性導入遺伝子発現を下方調節するためのマイクロｒｎａの利用

Also Published As

Publication number Publication date
EP2403527A4 (en) 2012-11-14
WO2010101663A3 (en) 2010-10-28
CA2754826A1 (en) 2010-09-10
US20120148622A1 (en) 2012-06-14
WO2010101663A2 (en) 2010-09-10
US8883995B2 (en) 2014-11-11
EP2403527A2 (en) 2012-01-11

Similar Documents

Publication Publication Date Title
US8883995B2 (en) Live attenuated influenza virus vaccines comprising microRNA response elements
Chen et al. Advances in development and application of influenza vaccines
US11180737B2 (en) Generation of infectious influenza viruses from virus-like particles
EP2010557B1 (en) High titer recombinant influenza viruses for vaccines
US8475807B2 (en) Avian influenza virus live attenuated vaccine and uses thereof
JP5491173B2 (ja) イヌ細胞中でマイナス鎖ウイルスｒｎａを発現させるための方法および組成物
US8278433B2 (en) Methods and compositions for expressing negative-sense viral RNA in canine cells
US20090324640A1 (en) Neuraminidase-deficient live influenza vaccines
US12350325B2 (en) Recombinant high growth rate influenza virus comprising mutations in M1, NS2, and PB2
US12569550B2 (en) Hemagglutinin modifications for improved influenza vaccine production
CN102361649A (zh) 流感血凝素和神经氨酸酶变体
JP6335167B2 (ja) 感染性インフルエンザウイルスの産生
JP6152535B2 (ja) 細胞培養組成物及びインフルエンザウイルスの生産方法
Groenke Molecular mechanism of virus attenuation by codon pair deoptimization
McMillen Development of Inducible Anti-influenza Therapies
HK1166277A (en) Influenza hemagglutinin and neuraminidase variants
MX2008000245A (en) Methods and compositionsfor expressing negative-sense viral rna in canine cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141028

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141203

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151208